EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioCardia's EBITDA for the
three
months ended in Mar. 2026 was €-1.96 Mil. BioCardia's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, BioCardia's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
BioCardia (STU:6JU0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioCardia EBITDA Margin % Related Terms
BioCardia EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioCardia's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6JU0 vs GRTX, CELU, KTTA: EBITDA Margin % Comparison
For the Biotechnology subindustry, BioCardia's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioCardia's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia (STU:6JU0) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioCardia and its competitors. According to the industry distribution chart, BioCardia ranks #999999 out of 938 companies in the Biotechnology industry.
Is BioCardia's EBITDA Margin % too high?
BioCardia's current EBITDA Margin % is 0.00%. Based on the distribution chart, BioCardia ranks #999999 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioCardia has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's EBITDA Margin % compare to GRTX and CELU?
According to the Biotechnology industry distribution chart, BioCardia ranks #999999 out of 938 companies for EBITDA Margin %. This places BioCardia in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioCardia and its competitors. BioCardia's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (STU:6JU0) has a current EBITDA Margin % of 0.00%. The stock's GF Value™ is €0.01, compared to a current price of €0.27 — trading 2600% above its estimated fair value. The current EBITDA Margin % is 0.00%. BioCardia's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioCardia (STU:6JU0), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCardia (STU:6JU0) Overvalued in 2026?
Based on GuruFocus' analysis, BioCardia stock appears to be overvalued.
The current stock price of €0.27 is trading 2600% above its estimated GF Value™ of €0.01.
Key valuation signals for STU:6JU0:
EBITDA Margin %: 0.00%
GF Value™: €0.01 vs. price of €0.27 (2600% above fair value)
No single metric tells the full story. See the STU:6JU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
17GF Score
Get the complete analysis for STU:6JU0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6JU0 has been successfully added to your 
